A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...

Pulmonary arterial hypertension causes the small lung arteries to become narrow, stiff, or thickened. PAH is often idiopathic ...

Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the lungs. Unlike common hypertension, PH specifically affects the pulmonary ...

It impacts the right side of the heart and arteries in the lungs. There can be various causes influencing the onset of ...

In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...

MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept ...

and pulmonary hypertension may be particularly relevant to the pathophysiology heart failure in patients with preserved ejection fraction, there is compelling rationale for extending the ...

When the pressure of blood within the walls of your arteries becomes ... it’s known as hypertension or high blood pressure. High blood pressure can have a variety of causes, and it can be ...

Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension: United Kingdom Friday, January 3, 2025, 17:00 Hrs ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ... number of typical potential causes, including infection ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...